Documents on display
Offeree / (Name of target company)
Shanghai Henlius Biotech, Inc. (Stock code : 02696)
Offeror
Shanghai Fosun New Medicine Research Company Limited (Stock code : -)
Document type
Composite Document
Document date
23 Dec 2024
Other website(s) on which the documents are displayed
http://www.henlius.com
Disclaimer: The documents on display have been provided to the SFC in electronic form by the issuers of offer documents, offeree board circulars or other documents issued under the Codes. These documents have not been reviewed by the Takeovers Executive. The provider of the documents on display takes full responsibility for the description and the information in the documents displayed.Please also refer to a separate disclaimer for more general guidance on the SFC's position on information on our website. In addition, please note that the documents are displayed on a best-effort basis and the SFC accepts no liability for any delay or error in the display of these documents.
The SFC does not own the copyright for any of the documents on display. By providing the documents on display to the SFC in accordance with the Codes, an issuer consents to these documents being downloaded or printed by users of our website solely for their personal use or for use within their firm or organisation.
Any user who wishes to reproduce for or distribute to third parties any of the documents on display or use them for commercial purposes should seek the consent of the relevant issuer. The SFC accepts no liability for any user who fails to seek or obtain such consent.
The SFC reserves the right, at its sole discretion, to remove any of the documents on display from its website. In any event, the documents on display will be removed from the SFC website upon the request of the relevant issuer after the end of the relevant offer period.
| Document description | Partition | Download |
|---|---|---|
| (001) Articles of Association of the Company (ENG) | All | |
| (002) Articles of Association of the Company (CHI) | All | |
| (003) 2024 Interim Report (ENG) | All | |
| (004) 2024 Interim Report (CHI) | All | |
| (005) 2023 Annual Report (ENG) | All | |
| (006) 2023 Annual Report (CHI) | All | |
| (007) 2022 Annual Report (ENG) | All | |
| (008) 2022 Annual Report (CHI) | All | |
| (009) 2021 Annual Report (ENG) | All | |
| (010) 2021 Annual Report (CHI) | All | |
| (011) Expert Consent Letter - Rainbow Capital | All | |
| (012) Merger Agreement | All | |
| (013) Supplemental Merger Agreement | All | |
| (014) Letter from the Board | All | |
| (015) Letter from the Independent Board Committee | All | |
| (016) Letter from the Independent Financial Adviser | All | |
| (017) Composite Document (ENG) | All | |
| (018) Composite Document (CHI) | All | |
| (019) Qualifying Shareholder Questionnaire | All |